P4HTM

P4HTM (P4H-TM/PH-4) is an endoplasmic reticulum-resident transmembrane prolyl 4-hydroxylase that acts as a non-redundant regulator of HIF-α stability and thereby of oxygen-dependent gene expression (PMID:12163023, PMID:42114683). Distinct from the cytoplasmic/nuclear EGLN prolyl hydroxylases, it localizes to the ER through an N-terminal anchor and carries an N-terminal EF-hand motif and a C-terminal catalytic domain; its overexpression suppresses HIF transactivation in an ODDD proline-dependent manner and lowers cellular HIF protein (PMID:12163023). Loss of P4H-TM stabilizes HIF-1α in normoxic neurons and drives constitutive HIF activation in vivo, with zebrafish epistasis demonstrating that the resulting erythrocytosis, cardiac, renal, and hepatic steatosis phenotypes are HIF-α dependent (PMID:27466183, PMID:42114683). In mice its highest expression spans RPE, brain, heart, lung, muscle, and kidney, and its loss produces retinal thinning, photoreceptor recycling defects, and renal lipid accumulation/fibrosis with age (PMID:27466183). A CNS-selective expression pattern in amygdala, lateral septum, and bed nucleus of the stria terminalis underlies a non-redundant role in fear, anxiety, and social behavior not shared by other HIF prolyl hydroxylases, and knockout mice further show disrupted circadian energy metabolism, muscle weakness, and a blunted ventilatory response to hypoxia and hypercapnia of neurological origin (PMID:31029587, PMID:38396259). Biallelic loss-of-function P4HTM variants, which destabilize or solubilize the protein, cause the severe neurological HIDEA syndrome (PMID:30940925).

1. 2002 Medium

   Established P4H-TM as a distinct, ER-localized prolyl 4-hydroxylase that can suppress HIF activity, raising the question of whether it is a bona fide oxygen-sensing enzyme separate from the EGLN family.

   Evidence Cellular reporter assays, overexpression, and subcellular localization in cultured cells

   PMID:12163023

   Open questions at the time

   • No in vitro enzymatic reconstitution or catalytic-residue mutagenesis
   • Direct hydroxylation of HIF prolines not demonstrated biochemically
2. 2013 Medium

   Showed P4HTM can lower HIF-2α and drive a downstream angiogenic program via TGF-α, linking its HIF-regulatory activity to tissue vascularization.

   Evidence Overexpression in osteosarcoma cells, HIF-2α western blot, in vitro sprouting and in vivo xenograft assays

   PMID:24048703

   Open questions at the time

   • Relies on overexpression rather than loss-of-function
   • No direct enzymatic assay of P4H-TM on HIF-2α
3. 2016 High

   Genetic loss-of-function in mice established P4H-TM as a physiological regulator of HIF-1α stability with tissue-specific consequences, moving beyond overexpression artifacts.

   Evidence P4h-tm-/- knockout mouse with HIF-1α western blot, HIF target qRT-PCR, electroretinography, and renal/retinal histology

   PMID:27466183

   Open questions at the time

   • Direct substrate hydroxylation not measured
   • Mechanism connecting HIF stabilization to retinal/renal pathology not fully resolved
4. 2019 Medium

   Defined a non-redundant CNS role for P4H-TM in anxiety and social behavior absent from other HIF prolyl hydroxylase isoforms, indicating isoform-specific neural function.

   Evidence Knockout mouse behavioral battery with brain expression mapping and isoform-specificity controls

   PMID:31029587

   Open questions at the time

   • Downstream molecular mechanism in CNS undefined
   • Whether behavioral phenotype is HIF-dependent not established
5. 2019 Medium

   Connected P4HTM to human disease, identifying biallelic loss-of-function variants as the cause of HIDEA syndrome and confirming variant proteins are functionally compromised.

   Evidence Exome sequencing with segregation, insect-cell expression and solubility assays of variant proteins

   PMID:30940925

   Open questions at the time

   • Solubility loss inferred rather than enzymatic activity measured
   • Genotype-phenotype mechanism in patients not dissected
6. 2021 Low

   Raised the possibility that P4H-TM function extends to mitochondrial homeostasis and additional substrates beyond HIF.

   Evidence Trio whole-genome sequencing and muscle complex I activity assay in a single patient

   PMID:34285383

   Open questions at the time

   • Single patient, single assay
   • Proposed targets (RNA Pol II, ATF4) not experimentally confirmed
   • Causal link between P4HTM loss and complex I deficiency not established
7. 2022 Low

   Consolidated the disease mechanism by showing all known pathogenic variants converge on loss of enzymatic function through truncation, deletion, or active-site/stability disruption.

   Evidence In silico structural/functional analysis of pathogenic variants across patients

   PMID:35908151

   Open questions at the time

   • Computational only; no biochemical reconstitution or mutagenesis
   • Predicted active-site impacts not validated functionally
8. 2023 Low

   Identified upstream transcriptional control of P4HTM, placing it downstream of GATA3 in breast cancer cells.

   Evidence ChIP-seq/genomics analysis and ectopic GATA3 overexpression with RT-qPCR (preprint)

   PMID:36909571

   Open questions at the time

   • Preprint, single overexpression experiment
   • No promoter reporter or binding-site mutagenesis confirming direct regulation
9. 2024 Medium

   Expanded the in vivo phenotype to systemic physiology, showing P4H-TM loss disrupts circadian energy metabolism, muscle strength, and respiratory chemosensitivity via CNS-attributed mechanisms.

   Evidence Knockout mouse indirect calorimetry, glucose/insulin tolerance, respiratory and sedation challenges

   PMID:38396259

   Open questions at the time

   • Upstream molecular mechanism not resolved
   • Tissue of origin (CNS vs peripheral) not genetically isolated
10. 2026 High

    Provided definitive pathway placement, demonstrating by epistasis that P4H-TM loss-of-function phenotypes are HIF-α-dependent and conserved across vertebrates.

    Evidence Zebrafish knockout with Hif-α inhibitor rescue and multi-organ phenotyping

    PMID:42114683

    Open questions at the time

    • Does not address HIF-independent functions (e.g. mitochondrial/CNS)
    • Direct hydroxylation chemistry still not reconstituted in vitro

• Whether P4H-TM directly hydroxylates HIF-α prolines (and any non-HIF substrates such as ATF4 or RNA Pol II) via reconstituted enzymatic activity, and how its ER localization and EF-hand motif shape substrate selection, remains unresolved.
• No direct biochemical demonstration of prolyl hydroxylation
• Non-HIF substrates unconfirmed
• Role of EF-hand/calcium sensing in catalysis unknown